At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Science & Technology
 



Home >> Science & Technology >> Pharmacological Chaperone Technology

Pharmacological Chaperone Monotherapy

Endogenous Protein Instability in Human Genetic Diseases
Many natural (endogenous) proteins are made in the endoplasmic reticulum (ER) and sent to other parts of the cell. Unstable, unfolded or misfolded proteins are generally eliminated or retained in the ER rather than being transported to the intended destination in the cell. The accumulation of unfolded or misfolded proteins in the ER and the interruption of trafficking of important proteins to their proper cellular locations can cause several types of problems:
  • Complete or partial loss of appropriate protein function
  • Accumulation of lipids and other substances that should be degraded
  • Disruption of cellular function and eventual cell death
These defects may lead to various types of human genetic diseases, including lysosomal storage disorders (LSDs).

Overview
Pharmacological chaperones as orally administered monotherapy agents have the potential to deliver new benefits to patients with human genetic diseases. Examples include certain LSDs, such as Gaucher and Fabry disease, as well as neurodegenerative diseases such as Parkinson’s disease.

Proposed Mechanism of Action
Loading the player ...


As monotherapy agents for lysosomal storage diseases, pharmacological chaperones are designed to bind to and stabilize endogenous protein (lysosomal enzyme) for proper trafficking to the lysosome, which also alleviates the toxic build-up of mutant proteins in the ER. Once in the lysosome, the pharmacological chaperone disassociates and the enzyme is free to break down substrate. Based on this mechanism, individuals with genetic mutations that result in some residual biological activity are potentially eligible for pharmacological chaperone monotherapy.


What's Missing in Lysosomal Storage Diseases?
(pdf - 1.6MB)



About Pharmacological Chaperones
(pdf - 640KB)




Glossary

Copyright © 2013 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy